Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
- 7 July 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (30), 13252-13257
- https://doi.org/10.1073/pnas.0913476107
Abstract
Due to its common dysregulation in epithelial-based cancers and extensive characterization of its role in tumor growth, epidermal growth factor receptor (EGFR) is a highly validated target for anticancer therapies. There has been particular interest in the development of monoclonal antibodies (mAbs) targeting EGFR, resulting in two approved mAb-based drugs and several others in clinical trials. It has recently been reported that treatment with combinations of noncompetitive mAbs can induce receptor clustering, leading to synergistic receptor down-regulation. We elucidate three key aspects of this phenomenon. First, we show that highly potent combinations consisting of two noncompetitive mAbs that target EGFR domain 3 reduce surface receptor levels by up to 80% with a halftime of 0.5–5 h in both normal and transformed human cell lines to an extent inversely proportional to receptor density. Second, we find the mechanism underlying down-regulation to be consistent with recycling inhibition. Third, in contrast to the agonism associated with ligand-induced down-regulation, we demonstrate that mAb-induced down-regulation does not activate EGFR or its downstream effectors and it leads to synergistic reduction in migration and proliferation of cells that secrete autocrine ligand. These new insights will aid in ongoing rational design of EGFR-targeted antibody therapeutics.This publication has 45 references indexed in Scilit:
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosisProceedings of the National Academy of Sciences of the United States of America, 2009
- EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulationJournal of Cell Science, 2007
- Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastomaProceedings of the National Academy of Sciences of the United States of America, 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface DisplayJournal of Molecular Biology, 2004
- EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain DimerizationMolecular Cell, 2003
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002
- Engineering dynamics of growth factors and other therapeutic ligandsBiotechnology & Bioengineering, 1996
- c-SRC Phosphorylates Epidermal Growth Factor Receptor on Tyrosine 845Biochemical and Biophysical Research Communications, 1995